RESUMO
Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004. The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.
Assuntos
Benzofuranos/efeitos adversos , Toxidermias/etiologia , Antagonistas Muscarínicos/efeitos adversos , Pirrolidinas/efeitos adversos , Benzofuranos/uso terapêutico , Toxidermias/patologia , Feminino , Granuloma/induzido quimicamente , Granuloma/patologia , Humanos , Pessoa de Meia-Idade , Antagonistas Muscarínicos/uso terapêutico , Pirrolidinas/uso terapêutico , Bexiga Urinária Hiperativa/tratamento farmacológicoRESUMO
Pamabron is a common over-the-counter diuretic used for relief of menstrual-associated symptoms. An urticarial eruption, with systemic complaints consistent with a serum sickness-like reaction, attributed to Pamabron is described. A review of the literature concerning Pamabron and dermatology is discussed.
Assuntos
Aspirina/efeitos adversos , Cafeína/efeitos adversos , Efedrina/análogos & derivados , Fenacetina/efeitos adversos , Propanolaminas/efeitos adversos , Doença do Soro/diagnóstico , Doença do Soro/etiologia , Teofilina/análogos & derivados , Adulto , Braço/patologia , Diagnóstico Diferencial , Combinação de Medicamentos , Efedrina/efeitos adversos , Feminino , Humanos , Perna (Membro)/patologia , Doença do Soro/patologia , Teofilina/efeitos adversosRESUMO
Acne vulgaris is a common skin disease affecting all ages. Antibiotics remain the most common prescribed agent for the treatment of acne. Improper use of antibiotics in the dermatological setting needs to be evaluated to prevent the increasing prevalence of antibiotic resistance.